IMIS | Flanders Marine Institute
 

Flanders Marine Institute

Platform for marine research

IMIS

Publications | Institutes | Persons | Datasets | Projects | Maps
[ report an error in this record ]basket (0): add | show Print this page

Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review
Polastro, L.; Aftimos, P.G.; Awada, A. (2014). Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review. Expert Review of Anticancer Therapy 14(6): 649-665. https://hdl.handle.net/10.1586/14737140.2014.920693
In: Expert Review of Anticancer Therapy. TAYLOR & FRANCIS LTD: Abingdon. ISSN 1473-7140; e-ISSN 1744-8328, more
Peer reviewed article  

Available in  Authors 

Author keywords
    breast cancer; chemotherapy; eribulin; review; solid tumor

Authors  Top 
  • Polastro, L.
  • Aftimos, P.G.
  • Awada, A.

Abstract
    In the new era of precision' cancer medicine, new drug development has shifted from cytotoxic chemotherapy to molecularly targeted agents. Eribulin mesylate, a microtubule-destabilizing agent, is the only classical' cytotoxic agent approved for the treatment of breast cancer in the last 7 years. This synthetic analogue of halichondrin B, isolated from the marine sponge Halicondria Okaida', was responsible for prolonging overall survival of heavily pretreated metastatic breast cancer patients in a large Phase III trial. Eribulin is now under clinical development in earlier settings such as the neo-adjuvant and adjuvant settings. Furthermore, its unique mechanism of action and the absence of cross-resistance with taxanes have led to the design of clinical trials in multiple indications: bladder cancer, lung cancer, prostate cancer... The main adverse events are neutropenia, fatigue and peripheral neuropathy.

All data in the Integrated Marine Information System (IMIS) is subject to the VLIZ privacy policy Top | Authors